Giuseppe Viale

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA
    Maria Olivia Biasi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 98:185-90. 2006
  2. ncbi The current state of breast cancer classification
    G Viale
    Department of Pathology, European Institute of Oncology, University of Milan, Milan, Italy
    Ann Oncol 23:x207-10. 2012
  3. ncbi International Web-based consultation on priorities for translational breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Breast Cancer Res 9:R81. 2007
  4. ncbi The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
    Christine Desmedt
    Institut Jules Bordet, , Brussels, Belgium
    BMC Med Genomics 2:40. 2009
  5. ncbi Pirin delocalization in melanoma progression identified by high content immuno-detection based approaches
    Silvia Licciulli
    Department of Experimental Oncology, Istituto Europeo di Oncologia, Via Adamello 16, 20139, Milan, Italy
    BMC Cell Biol 11:5. 2010
  6. ncbi Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
    Janine Antonov
    Department of Clinical Research, University of Bern, Bern, Switzerland
    BMC Cancer 10:37. 2010
  7. ncbi Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
    Filippo Montemurro
    Divisione di Oncologia Medica, AO Ordine Mauriziano Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italy
    BMC Cancer 8:209. 2008
  8. ncbi Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
    Stefania Redana
    Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo Italy
    BMC Cancer 10:28. 2010
  9. ncbi Sensitivity of imaging for multifocal-multicentric breast carcinoma
    Anna Bozzini
    Breast Imaging Unit, Department of Radiology, European Institute of Oncology, Via Ripamonti 435 20141 Milan, Italy
    BMC Cancer 8:275. 2008
  10. ncbi Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Universita degli Studi di Milano, Milan, Italy
    J Pathol 219:1-2. 2009

Detail Information

Publications127 found, 100 shown here

  1. ncbi Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA
    Maria Olivia Biasi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 98:185-90. 2006
    ....
  2. ncbi The current state of breast cancer classification
    G Viale
    Department of Pathology, European Institute of Oncology, University of Milan, Milan, Italy
    Ann Oncol 23:x207-10. 2012
    ....
  3. ncbi International Web-based consultation on priorities for translational breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Breast Cancer Res 9:R81. 2007
    ..We therefore conducted an international Web-based consultation of breast cancer professionals to identify the topics most widely considered to be of highest priority...
  4. ncbi The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
    Christine Desmedt
    Institut Jules Bordet, , Brussels, Belgium
    BMC Med Genomics 2:40. 2009
    ..Validation of these results, in a larger series from BIG 1-98, is planned using the simplified GGI represented by a smaller set of genes and tested by qRT-PCR on paraffin-embedded tissues...
  5. ncbi Pirin delocalization in melanoma progression identified by high content immuno-detection based approaches
    Silvia Licciulli
    Department of Experimental Oncology, Istituto Europeo di Oncologia, Via Adamello 16, 20139, Milan, Italy
    BMC Cell Biol 11:5. 2010
    ..Although its precise role in these functions has not yet been defined, PIR expression is known to be deregulated in several human malignancies...
  6. ncbi Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
    Janine Antonov
    Department of Clinical Research, University of Bern, Bern, Switzerland
    BMC Cancer 10:37. 2010
    ..The purpose of the work reported here is to test reliable molecular profiles using routinely processed formalin-fixed paraffin-embedded (FFPE) tissues from participants of the clinical trial BIG 1-98 with a median follow-up of 60 months...
  7. ncbi Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
    Filippo Montemurro
    Divisione di Oncologia Medica, AO Ordine Mauriziano Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italy
    BMC Cancer 8:209. 2008
    ..We sought to document the clinical activity of vinorelbine-based salvage treatments in this clinical setting...
  8. ncbi Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
    Stefania Redana
    Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo Italy
    BMC Cancer 10:28. 2010
    ..We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations...
  9. ncbi Sensitivity of imaging for multifocal-multicentric breast carcinoma
    Anna Bozzini
    Breast Imaging Unit, Department of Radiology, European Institute of Oncology, Via Ripamonti 435 20141 Milan, Italy
    BMC Cancer 8:275. 2008
    ....
  10. ncbi Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Universita degli Studi di Milano, Milan, Italy
    J Pathol 219:1-2. 2009
    ..This is central to ensuring that all who may respond to potentially life-saving treatment with herceptin/lapatininib are not denied these drugs...
  11. ncbi Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment
    Giuseppe Viale
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Via Ripamonti 435, Milan, Italy
    Breast 18:S32-6. 2009
    ..The actual clinical utility of the molecular assays is being tested in randomized clinical trials that require an unprecedented coordination of the activity of clinical investigators, pathologists and translational researchers worldwide...
  12. ncbi Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
    G Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    Ann Oncol 21:245-54. 2010
    ..Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer...
  13. ncbi Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution
    Giuseppe Viale
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Milan, Italy
    Cancer 103:492-500. 2005
    ....
  14. ncbi Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy
    Giuseppe Viale
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Ann Surg 241:319-25. 2005
    ..To assess whether the risk for nonsentinel node metastases may be predicted, thus sparing a subgroup of patients with breast carcinoma and a positive sentinel lymph node (SLN) biopsy completion axillary lymph node dissection (ALND)...
  15. ncbi Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  16. ncbi Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..EGFR immunoreactivity significantly correlates with worse prognosis in patients with triple-negative IDC, supporting further studies on the correlation between the degree of EGFR expression and outcome of triple negative breast cancer...
  17. ncbi Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  18. ncbi Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience
    Giuseppe Viale
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti, 435, Milan, Italy
    Virchows Arch 448:241-7. 2006
    ....
  19. ncbi Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series
    Giuseppe Viale
    European Institute of Oncology, University of Milan, Italy
    Breast Cancer Res Treat 117:211-4. 2009
    ..Classical lobular histology is not an independent factor in the prognosis of early breast cancer...
  20. ncbi Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
    ....
  21. ncbi Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients
    Giuseppe Viale
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Ann Surg 247:136-42. 2008
    ....
  22. ncbi Pathological definitions of invasion, metastatic potential and responsiveness to targeted therapies
    Giuseppe Viale
    Department of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Breast 16:S55-8. 2007
    ....
  23. ncbi Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
    ..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer...
  24. ncbi Pathological work up of the primary tumor: getting the proper information out of it
    Giuseppe Viale
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    Breast 20:S82-6. 2011
    ....
  25. ncbi What can the pathologist offer for optimal treatment choice?
    G Viale
    Department of Pathology, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Ann Oncol 21:vii27-9. 2010
    ..To minimize the risk of inducing inappropriate changes in systemic treatments due to false-positive or false-negative results, the pathologists should make all efforts to improve accuracy and reproducibility of the assay procedures...
  26. ncbi Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma
    G Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Cancer 92:1378-84. 2001
    ....
  27. ncbi Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients
    Giuseppe Viale
    University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    J Surg Oncol 85:123-8. 2004
    ..Herein, a very stringent protocol for the examination of the axillary SLN is reported, which is applied either to frozen SLN for the intraoperative diagnosis, and to fixed and embedded SLN as well...
  28. ncbi Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
    G Viale
    International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    Ann Oncol 22:2201-7. 2011
    ..Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important...
  29. ncbi Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Cancer 103:1154-64. 2005
    ..To the authors' knowledge, little is known regarding the role of E-cadherin/beta-catenin system dysregulation in pulmonary neuroendocrine tumors...
  30. ncbi A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:621-8. 2012
    ..To develop a Risk Score (RS) to predict distant recurrence among premenopausal women with node-negative endocrine-responsive early breast cancer...
  31. ncbi Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
    ..A non-negligible rate of progressive disease was observed, suggesting careful monitoring of the patients. Further studies evaluating the potential benefit of bevacizumab in neoadjuvant treatment need to be tested...
  32. ncbi Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
    ..No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors...
  33. ncbi A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
    ..Perioperative chemotherapy failed to show an increase in the pathological complete remission rate. A biological effect on Ki-67 expression was demonstrated...
  34. ncbi Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
    Laura Orlando
    Research Unit Medical Senology, European Institute of Oncology, Milan, Italy
    Breast 17:506-11. 2008
    ..We analyzed the role of Topo II gene status in the prediction of pathological complete remission (pCR) after primary anthracycline-based chemotherapy in non- endocrine responsive breast cancers overexpressing Her2/neu...
  35. ncbi Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 20:34-8. 2011
    ..To explore the activity of pegylated liposomal doxorubicin (PLD) as neoadjuvant therapy of breast cancer...
  36. ncbi Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Marco Colleoni
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Universita degli Studi di Milano, Milan, Italy
    J Clin Oncol 28:2966-73. 2010
    ....
  37. ncbi Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Cancer 113:101-8. 2005
    ..Among neuroendocrine tumours, LCNEC show a slightly higher prevalence of either HER-2/neu gene amplification or protein overexpression...
  38. ncbi Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
    Emilia Montagna
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 124:689-99. 2010
    ..A substantial rate of relapse was observed for patients with large tumors and with clinical nodal involvement at baseline. Further improvement in adjuvant treatment might be warranted...
  39. ncbi Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study
    Umberto Veronesi
    Scientific Direction, European Institute of Oncology, Milan, Italy
    Lancet Oncol 7:983-90. 2006
    ..Results of our previous trial showed that SLNB accurately screens the ALN for metastasis in breast cancers of diameter 2 mm or less. We aimed to update this trial with results from longer follow-up...
  40. ncbi Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:905-12. 2004
    ..Synchronous bilateral invasive breast carcinoma (SBIBC) ranged in incidence from 0.3% to as high as 12%...
  41. ncbi Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center
    Emilio Bertani
    Division of General and Laparoscopic Surgery, European Institute of Oncology, University of Milan, Milan, Italy
    Dig Surg 27:297-301. 2010
    ..During the last 10 years, chemoradiation treatment (CRT) has been considered the standard of care for anal cancer...
  42. ncbi Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Clin Cancer Res 11:242-8. 2005
    ..To analyze the prevalence and clinical relevance of cyclin D3 abnormalities in laryngeal squamous cell carcinoma (LSCC)...
  43. ncbi Conservative treatment of breast cancer: its evolution
    Alberto Luini
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 94:195-8. 2005
    ..From an oncological perspective, outcome was found to be equally effective, and this key observation provided us with significant impetus to investigate the effects of reducing the radiotherapy field...
  44. ncbi A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer
    Umberto Veronesi
    Division of Senology, European Institute of Oncology, Milan, Italy
    N Engl J Med 349:546-53. 2003
    ..Although numerous studies have shown that the status of the sentinel node is an accurate predictor of the status of the axillary nodes in breast cancer, the efficacy and safety of sentinel-node biopsy require validation...
  45. ncbi Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory MedicineEuropean Institute of Oncology and National Cancer Institute, Milan, Italy
    Anticancer Res 30:4269-81. 2010
    ..Little is known about the dual role of RAS-association domain family 1 (RASSF1) gene at 3p21.3 in neuroendocrine tumors (NET) of the lung...
  46. ncbi Effectiveness of LigaSure diathermy coagulation in liver surgery
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, University of Milan, Milan, Italy
    Surg Technol Int 17:33-8. 2008
    ..The LigaSure device in this randomized study is safe and simple to use, resulting in less perioperative blood loss and transfusion requirement during hepatic parenchymal transection...
  47. ncbi Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
    ..Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer...
  48. ncbi A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Virchows Arch 447:969-77. 2005
    ..A minor subset of these tumors shows beta-catenin nuclear accumulation in association with increased expression of MMP-7, but not of cyclin D1, independent of EGFR and HER-2 gene amplification or expression...
  49. ncbi The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Pathol 206:337-45. 2005
    ..Our data suggest that TA-p63 is overexpressed in high-grade FL, possibly independent of the occurrence of gene abnormalities, and that it may be involved in the highly complex mechanism of regulation of apoptosis of FL cells...
  50. ncbi Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Ann Surg 247:315-9. 2008
    ....
  51. ncbi Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 20:319-23. 2011
    ..To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer...
  52. ncbi Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:359-69. 2009
    ..4, 95% CI 3.5-11.6, for DFS; HR 3.6 95% CI 2.4-5.6 for OS). Response and outcome after PCT are correlated with the degree of expression of steroid hormone receptors. Studies on tailored preoperative therapies are needed...
  53. ncbi Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
    Viviana Galimberti
    Division of Senology, Unit of Molecular Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 131:819-25. 2012
    ..Nevertheless, a subset of patients might be at high risk of developing overt axillary disease and efforts should be made to identify such patients by ancillary analyses of the results of ongoing or recently published clinical trials...
  54. ncbi Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, Milano, Italy
    Hepatogastroenterology 56:829-34. 2009
    ....
  55. ncbi 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine and Cancer Genetic Unit, IFOM Foundation FIRC Institute of Molecular Oncology Foundation, Milan, Italy
    Clin Cancer Res 13:1995-2004. 2007
    ....
  56. ncbi Alterations of the Notch pathway in lung cancer
    Britta Westhoff
    IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
    Proc Natl Acad Sci U S A 106:22293-8. 2009
    ..Our results show that the deregulation of the Notch pathway is a relatively frequent event in NSCLCs and suggest that it might represent a possible target for molecular therapies in these tumors...
  57. ncbi Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer
    Andrea Rocca
    Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 29:5111-9. 2009
    ..The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear...
  58. ncbi Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study
    Umberto Veronesi
    European Institute of Oncology, Milan, Italy
    Ann Surg 251:595-600. 2010
    ..We present 10-year follow-up of our single-institute trial designed to compare outcomes in patients who received no axillary dissection if the sentinel node was negative, with patients who received complete axillary dissection...
  59. ncbi Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection
    Umberto Veronesi
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:231-7. 2005
    ..The 5 year overall survival rate of the whole series was 98%. Patients with negative sentinel node biopsies not submitted to axillary dissection show during follow-up a rate of overt axillary metastases that is lower than that expected...
  60. ncbi Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement
    Marco Colleoni
    Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 23:1379-89. 2005
    ....
  61. ncbi Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation
    Emilia Montagna
    Division of Medical Oncology, Department of Medicine, Unit Research of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 129:867-75. 2011
    ..The outcome of OBC patients is comparable with that of matched patients with small sized breast cancer. High risk of relapse and death was observed in OBC patients with triple negative tumours and extensive nodal involvement...
  62. ncbi Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity
    Emilia Montagna
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 12:207-14. 2012
    ..The analysis of the results suggests that the metronomic chemotherapy combined with bevacizumab and erlotinib is effective and well tolerated...
  63. ncbi Local therapy for breast cancer in malignant lymphoma survivors
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Breast 20:S99-103. 2011
    ..We performed a retrospective review to assess the potential of performing breast conservative surgery and intraoperative radiotherapy with electrons (ELIOT), in these patients...
  64. ncbi Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:483-8. 2010
    ..Given its low cardiotoxicity, the combination of PLD and trastuzumab appears most attractive in the treatment of human epidermal factor receptor 2 (HER2)-positive breast cancer...
  65. ncbi Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Virchows Arch 458:497-503. 2011
    ..This tumor had probably derived for clonal evolution of a p53-mutated common ancestor lesion...
  66. ncbi Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
    Breast Cancer Res Treat 126:431-41. 2011
    ....
  67. ncbi A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Eur J Cancer 46:2216-24. 2010
    ..Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome...
  68. ncbi The surgical margin status after breast-conserving surgery: discussion of an open issue
    Alberto Luini
    Senology Division, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 113:397-402. 2009
    ..Radiation therapy could be a good option in the management of these cases, but further evidence is needed to establish the real impact of clear surgical margins on local control of disease and, furthermore, on survival...
  69. ncbi Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy
    Ann Surg Oncol 12:895-9. 2005
    ..Although a previous SLNB is often considered a contraindication for a subsequent SLNB, few data support this concern...
  70. ncbi Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    Marco Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6622-8. 2004
    ..The purpose of this research was to identify factors predicting response to preoperative chemotherapy...
  71. ncbi CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:711-21. 2004
    ..Targeting the CD117 pathway could be a novel therapeutic strategy in a subset of pulmonary carcinomas...
  72. ncbi CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Virchows Arch 445:449-55. 2004
    ..There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients...
  73. ncbi Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients
    Roberto Gennari
    Department of Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:1302-10. 2004
    ..The aim of the study was to evaluate the relation between biologic features at first diagnosis of breast carcinoma and treatment choice for postmenopausal women > or = 50 years to optimize treatment in the elderly...
  74. ncbi Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Int J Cancer 112:71-7. 2004
    ..Our data suggest that the t(6;14) translocation may be extremely uncommon in FL and that a deregulated expression of cyclin D3, possibly due to epigenetic mechanisms, may be involved in the pathogenesis of high-grade tumors...
  75. ncbi K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:538-46. 2004
    ....
  76. ncbi Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, School of Medicine, Italy
    Hum Pathol 34:41-7. 2003
    ..Our data suggest that the immunohistochemical evaluation of p53 IR in bone marrow biopsies may represent an adjunct in MM patient prognostication...
  77. ncbi Review article: pulmonary sarcomatoid carcinomas: a practical overview
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, University of Milan School of Medicine, Milan
    Int J Surg Pathol 18:103-20. 2010
    ..Conceivably, targeting the epithelial-mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing...
  78. ncbi p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Lab Invest 82:1327-34. 2002
    ....
  79. ncbi Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy
    Umberto Veronesi
    Scientific Directorate, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 99:727-37. 2007
    ..Here we present an extended follow-up of the Italian trial...
  80. ncbi Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years
    Aliana Guerrieri-Gonzaga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Oncologist 14:201-12. 2009
    ..We analyzed risk factors and treatment outcome in a large series of women treated at one institution...
  81. ncbi The sentinel node biopsy under local anesthesia in breast cancer: advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases
    Alberto Luini
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Breast 16:527-32. 2007
    ..We are now discussing the impact of the SLNB under local anesthesia on the activity of a breast surgery department. We also present an update of our experience...
  82. ncbi The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life
    Alberto Luini
    Senology Division, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 89:69-74. 2005
    ..We previously published our preliminary experience with 115 patients; here we present an update of our experience with particular attention devoted to quality of life...
  83. ncbi Surgical outcomes after total mesorectal excision for rectal cancer
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, University of Milan, Milan, Italy
    J Surg Oncol 94:182-93; discussion 181. 2006
    ..This study reviewed the results of surgery for distal rectal cancer following the introduction of total mesorectal excision (TME) for rectal cancer...
  84. ncbi A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer
    Nicoletta Colombo
    Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy
    Cancer Epidemiol Biomarkers Prev 15:1914-9. 2006
    ..Under our experimental conditions, 4-HPR did not show activity in advanced ovarian cancer cells. However, clinical evidence supports further investigation of fenretinide for ovarian cancer prevention...
  85. ncbi Sentinel node detection in pre-operative axillary staging
    Giuseppe Trifiro
    Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy
    Eur J Nucl Med Mol Imaging 31:S46-55. 2004
    ..Nowadays, lymphoscintigraphy is a useful procedure in patients with different clinical evidence of breast cancer...
  86. ncbi Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome
    Maurilio Ponzoni
    Department of Pathology, San Raffaele H Scientific Institute, Milan, Italy
    Int J Cancer 106:288-91. 2003
    ..Accordingly, patients with CD10(+) gastric large B-cell lymphomas may be at reduced risk and eligible for clinical trials evaluating more conservative therapeutic options...
  87. ncbi An alternative viewpoint
    Giuseppe Viale
    European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 12:307-9. 2004
  88. ncbi Surgical treatment of advanced colorectal cancer in the elderly
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, University of Milan
    Chir Ital 57:589-96. 2005
    ..0001) correlated significantly with overall survival rates in the elderly. Colorectal surgery for malignancy can be performed safely in the elderly with acceptable morbidity and mortality rates and long-term survival...
  89. ncbi Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation
    Giancarlo Pruneri
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Mod Pathol 16:886-92. 2003
    ..066) only. These data suggest that cyclin D3 expression in GISTs is independent of gene amplification and that this protein may be involved in the pathogenesis of GISTs by counteracting the inhibitory activities of p27...
  90. ncbi Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis
    Salvatore Pece
    Istituto Europeo di Oncologia, 20141 Milan, Italy
    J Cell Biol 167:215-21. 2004
    ..Thus, the Numb/Notch biological antagonism is relevant to the homeostasis of the normal mammary parenchyma and its subversion contributes to human mammary carcinogenesis...
  91. ncbi Follicular dendritic cell sarcoma of the breast
    Giancarlo Pruneri
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, School of Medicine, Via Ripamonti 435, 20141, Milan, Italy
    Virchows Arch 441:194-9. 2002
    ..The post-surgical course of the patient was uneventful and she is currently free of disease 19 months after surgery...
  92. ncbi Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining
    Maurilio Ponzoni
    Department of Pathology, San Raffaele H Scientific Institute, Milan, Italy
    Mod Pathol 17:1513-20. 2004
    ..These findings provide a rationale for the investigational use of anti-CD105-targeted drugs in CIMF...
  93. ncbi Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response
    Laura Lavinia Travaini
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:262-70. 2007
    ..The absence of any association between tumor uptake and washout with respect to therapy response suggests that MMS is not a reliable technique to predict therapy response in LABC...
  94. ncbi Adenomyoepithelioma of the breast, presenting as a cancer
    Giovanna Gatti
    Senology Division, European Oncology Institute, Milan, Italy
    Tumori 90:337-9. 2004
    ..Adenomyoepithelioma is a rare lesion that can involve the breast tissue. The diagnostic appearance of the lesion can give rise to a difficult differential diagnosis with breast carcinoma...
  95. ncbi The evolution of the conservative approach to breast cancer
    Alberto Luini
    Division of Breast Surgery, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 16:120-9. 2007
    ..For this reason in our Institute we are now evaluating the feasibility of a reduction of the radiation field and the sensibility and sensitivity of new diagnostic approaches for axillary staging...
  96. ncbi Intravascular papillary endothelial hyperplasia of the renal vein
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 19:518-20. 2011
    ....
  97. ncbi A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, and University of Milan School of Medicine, Milan, Italy
    J Natl Cancer Inst 95:779-90. 2003
    ....
  98. ncbi Rethinking TNM: breast cancer TNM classification for treatment decision-making and research
    Umberto Veronesi
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 15:3-8. 2006
    ..The significant changes we propose are:..
  99. ncbi Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Institute of European Oncology and University of Milan School of Medicine, Italy
    Am J Surg Pathol 27:1203-15. 2003
    ....
  100. ncbi Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis
    Fausto Maffini
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Cutan Pathol 36:689-91. 2009
    ....
  101. ncbi Branchiogenic carcinoma--conceptual or true clinico-pathological entity?
    Barbara A Jereczek-Fossa
    Department of Radiation Oncology, European Institute of Oncology, 435 Via Ripamonti, 20141 Milan, Italy
    Cancer Treat Rev 31:106-14. 2005
    ..The existence of true branchiogenic carcinoma remains to be verified with new clinical and molecular criteria...